Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Why Tilray (TLRY) Stock Is Down Today

November 14, 2025 at 11:35 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

TLRY Cover Image

What Happened?

Shares of cannabis company Tilray Brands (NASDAQ: TLRY) fell 1.8% in the morning session after the U.S. government passed a spending bill that included provisions to re-criminalize certain hemp-derived THC products.

The last-minute provision effectively targeted intoxicating hemp products, such as Delta-8, that had been legalized under the 2018 Farm Bill. This development was viewed as a setback for Canadian cannabis companies like Tilray, which had considered the hemp-derived product segment a key pathway into the lucrative U.S. market. In response to the legislative change, Tilray stated that it expected “no material revenue impact” from the ban.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Tilray? Access our full analysis report here.

What Is The Market Telling Us

Tilray’s shares are extremely volatile and have had 85 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was about 2 months ago when the stock gained 41.4% on the news that U.S. President Donald Trump endorsed the use of cannabidiol (CBD) for senior healthcare in a social media post.

Over the weekend, Trump posted on his Truth Social platform, suggesting that hemp-derived CBD could 'revolutionize senior healthcare' and serve as an alternative to prescription drugs. His comments acted as a major catalyst for the cannabis industry, sparking a broad rally that lifted shares of other major players like Canopy Growth and Aurora Cannabis. This endorsement fueled investor optimism regarding the potential for wider adoption of CBD products and a more favorable regulatory environment, adding to existing hopes for the reclassification of marijuana.

Tilray is down 23.6% since the beginning of the year, and at $1.12 per share, it is trading 46.9% below its 52-week high of $2.10 from October 2025.

Microsoft, Alphabet, Coca-Cola, Monster Beverage—all began as under-the-radar growth stories riding a massive trend. We’ve identified the next one: a profitable AI semiconductor play Wall Street is still overlooking.Go here for access to our full report.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article